Plasma levels of miR-106b-5p and miR-185-5p were significantly increased in patients with chronic heart failure compared to matched non-HF subjects.
Case-Control (n=82)
Are plasma levels of miR-106b-5p and miR-185-5p altered in patients with chronic heart failure compared to non-HF subjects?
Plasma levels of miR-106b-5p and miR-185-5p are significantly elevated in chronic heart failure and may serve as potential biomarkers or therapeutic targets.
Heart failure (HF) is one of the largest contributors to disease burden and healthcare expenditure worldwide. Countless studies have shown that microRNAs (miRNAs) are pivotal regulators of heart homeostasis and promising biomarkers for the diagnosis and management of HF. Among the reported miRNAs, miR-106b-5p and miR-185-5p have been implicated in various cardiovascular diseases through involvement in cardiac injury, fibrosis, and cell survival pathways. Although cellular functions of miR-106b-5p and miR-185-5p have been investigated intensively, their circulating levels remain largely elusive in patients with HF. This study examined expression levels of plasma miR-106b-5p and miR-185-5p by quantitative reverse transcription PCR (RT-qPCR) in a study cohort comprising 41 chronic HF patients and 41 matched, non-HF subjects. Bioinformatic analysis was conducted for miR-106b-5p and miR-185-5p to discover their potential target genes, biological functions, and association with cardiovascular-related clinical phenotypes. Chronic HF patients presented a significant increase in plasma miR-106b-5p and miR-185-5p levels. Diverse expressive patterns of miR-106b-5p and miR-185-5p were observed in different types and functional classes of HF. A positive correlation between plasma miR-106b-5p and miR-185-5p was also identified. In silico analysis suggested that many genes related to cell proliferation and metabolic pathways were shared targets of miR-106b-5p and miR-185-5p. Our study reveals dysregulation of plasma miR-106b-5p and miR-185-5p in patients with chronic HF that may contribute to the pathological course of this disease.
Huynh et al. (Mon,) conducted a case-control in Chronic Heart Failure (n=82). Plasma miR-106b-5p and miR-185-5p levels vs. Matched non-HF subjects was evaluated on Expression levels of plasma miR-106b-5p and miR-185-5p. Plasma levels of miR-106b-5p and miR-185-5p were significantly increased in patients with chronic heart failure compared to matched non-HF subjects.